CO2022009239A2 - Polipéptidos que comprenden dominios variables únicos de inmunoglobulina dirigidos a tnfα e il-23 - Google Patents

Polipéptidos que comprenden dominios variables únicos de inmunoglobulina dirigidos a tnfα e il-23

Info

Publication number
CO2022009239A2
CO2022009239A2 CONC2022/0009239A CO2022009239A CO2022009239A2 CO 2022009239 A2 CO2022009239 A2 CO 2022009239A2 CO 2022009239 A CO2022009239 A CO 2022009239A CO 2022009239 A2 CO2022009239 A2 CO 2022009239A2
Authority
CO
Colombia
Prior art keywords
variable domains
polypeptides
immunoglobulin variable
single immunoglobulin
present technology
Prior art date
Application number
CONC2022/0009239A
Other languages
English (en)
Spanish (es)
Inventor
Heidi Rommelaere
Ann Brigé
Sigrid Cornelis
Eric Lorent
Christian Asbrand
Original Assignee
Sanofi Sa
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Ablynx Nv filed Critical Sanofi Sa
Publication of CO2022009239A2 publication Critical patent/CO2022009239A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CONC2022/0009239A 2019-12-06 2022-07-01 Polipéptidos que comprenden dominios variables únicos de inmunoglobulina dirigidos a tnfα e il-23 CO2022009239A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962944619P 2019-12-06 2019-12-06
EP20305056 2020-01-23
EP20000090 2020-02-28
EP20305216 2020-03-02
PCT/EP2020/084430 WO2021110816A1 (en) 2019-12-06 2020-12-03 POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23

Publications (1)

Publication Number Publication Date
CO2022009239A2 true CO2022009239A2 (es) 2022-07-29

Family

ID=73642903

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0009239A CO2022009239A2 (es) 2019-12-06 2022-07-01 Polipéptidos que comprenden dominios variables únicos de inmunoglobulina dirigidos a tnfα e il-23

Country Status (14)

Country Link
US (4) US20210188963A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069733A1 (cg-RX-API-DMAC7.html)
JP (1) JP7657797B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220122652A (cg-RX-API-DMAC7.html)
CN (1) CN114981300B (cg-RX-API-DMAC7.html)
AU (1) AU2020396204A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022009799A2 (cg-RX-API-DMAC7.html)
CA (1) CA3163877A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022009239A2 (cg-RX-API-DMAC7.html)
IL (1) IL293561A (cg-RX-API-DMAC7.html)
MX (1) MX2022006880A (cg-RX-API-DMAC7.html)
PH (1) PH12022551214A1 (cg-RX-API-DMAC7.html)
TW (1) TW202134269A (cg-RX-API-DMAC7.html)
WO (1) WO2021110816A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
LT3248986T (lt) 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
WO2020144164A1 (en) 2019-01-07 2020-07-16 Bactolife Aps Pathogen binding proteins
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
EP4069733A1 (en) 2019-12-06 2022-10-12 Ablynx N.V. POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFalpha AND IL-23
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
EP4438614A1 (en) 2023-03-31 2024-10-02 Sanofi Methods for purifying heteromultimeric antibodies
US20250236673A1 (en) * 2023-12-22 2025-07-24 Ablynx N.V. Protein-based carriers for site-specific amine conjugation
CN118687298A (zh) 2024-07-29 2024-09-24 上海原能细胞生物低温设备有限公司 一种立式低温存储冰箱
CN119371530B (zh) * 2024-11-06 2025-05-20 北京科道博济生物科技有限公司 一种靶向il-23a的纳米抗体及其应用
CN121824755A (zh) * 2026-01-16 2026-04-10 天津科道博济生物科技有限公司 一种靶向il-23a的纳米检测抗体及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
AU2007237501A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. DP-78-like nanobodies
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン.ヴェー. Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド
CA2706425A1 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
LT3466972T (lt) 2011-06-23 2026-06-25 Ablynx Nv Serumo albuminą surišantys baltymai
LT3248986T (lt) 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
EP3365371B1 (en) * 2015-10-22 2025-10-08 Ablynx NV Gitr agonists
NO2768984T3 (cg-RX-API-DMAC7.html) 2015-11-12 2018-06-09
HUE057241T2 (hu) 2015-11-13 2022-04-28 Ablynx Nv Javított, szérumalbumint kötõ immunoglobulin variábilis domének
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
EP3414268A1 (en) * 2016-02-12 2018-12-19 Ablynx NV Method for the production of immunoglobulin single variable domains
WO2018104444A1 (en) 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
EP3571224B1 (en) 2017-01-17 2024-08-07 Ablynx NV Improved serum albumin binders
EP4442709A3 (en) 2017-01-17 2024-12-25 Ablynx NV Improved serum albumin binders
AR112341A1 (es) 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
EP4069733A1 (en) 2019-12-06 2022-10-12 Ablynx N.V. POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFalpha AND IL-23

Also Published As

Publication number Publication date
US11332525B2 (en) 2022-05-17
CN114981300B (zh) 2025-10-31
US12528860B2 (en) 2026-01-20
EP4069733A1 (en) 2022-10-12
US20220064281A1 (en) 2022-03-03
TW202134269A (zh) 2021-09-16
PH12022551214A1 (en) 2023-10-09
AU2020396204A1 (en) 2022-07-28
KR20220122652A (ko) 2022-09-02
BR112022009799A2 (pt) 2022-08-16
US20220363747A1 (en) 2022-11-17
CN114981300A (zh) 2022-08-30
WO2021110816A1 (en) 2021-06-10
JP7657797B2 (ja) 2025-04-07
US20210188963A1 (en) 2021-06-24
CA3163877A1 (en) 2021-06-10
IL293561A (en) 2022-08-01
US20220372128A1 (en) 2022-11-24
JP2023505492A (ja) 2023-02-09
MX2022006880A (es) 2022-07-11

Similar Documents

Publication Publication Date Title
MX2022006880A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa e il-23.
CO2022008576A2 (es) Polipéptidos que comprenden dominios variables únicos de inmunoglobulina dirigidos a tnfα y ox40l
CO2022008813A2 (es) Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
AR120698A1 (es) Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
CO2023009231A2 (es) Polipéptidos que comprenden dominios variables simples de inmunoglobulina dirigidos a glypican-3 y al receptor de células t
MX2022006461A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
EA202091976A1 (ru) Вариабельные домены антител, нацеленные на cd33, и их применение
CO2020010345A2 (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d
CO2018009533A2 (es) Conjugados de amanitina
DOP2019000011A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
CO2023002989A2 (es) Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y ox40l
EA201990861A1 (ru) Рнк-направляемые модифицирующие нуклеиновые кислоты ферменты и способы их применения
BR112017003194B8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição
UY36536A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
WO2020172596A8 (en) Anti-tcr antibody molecules and uses thereof
BR112019008859A2 (pt) anticorpos direcionados contra a morte programada 1 (pd-1)
MX2024010990A (es) Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control.
BR112016014293A2 (pt) região de fragmento cristalizável canino, anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, e, método para aumentar a atividade de uma célula imune
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
MX2017016674A (es) Inmunoglobulinas conjugadas en cys80.
MX2021007677A (es) Proteinas de union multiespecificas basadas en pseudofab.
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение
WO2017192946A8 (en) MONOCLONAL DNA ANTIBODIES TARGETING INFLUENZA VIRUS
BR112022009223A2 (pt) Moléculas de anticorpo anti-siglec-9